Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 196

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 196
---
, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate                                                                               Europe             Not Applicable                                                                                                                          Compound for use  
  and derivatives thereof for treating circadian rhythm sleep disorders with or without neurodegenerative diseases                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                
  EP 21305942.1                                                                                                                                                                                                                                                                                                                 
  Benedin, Piperidine, 2-benzhydryl-3-hydroxy-N-methyl-, hydrochloride                                                                             Europe             Not Applicable                                                                                                                          Compound for use  
  and derivatives thereof for treating neurological diseases associated with sleep disorders, Central Disorders of Hypersomnolence preferably                                                                                                                                                                                   
  Kleine-Levin Syndrome                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                
  EP 21305946.2                                                                                                                                                                                                                                                                                                                 
  Lauflumide and derivatives thereof for treating chronic fatigue                                                                                  Europe             Not Applicable                                                                                                                          Compound for use  
  syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                
  EP 21305944.7                                                                                                                                                                                                                                                                                                                 
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

In addition to our patents
and patent applications, we also rely on unpatented trade secrets, know-how, and continuing technological innovation to develop and maintain
our competitive position. We seek to protect our ownership of know-how and trade secrets through an active program of legal mechanism
including invention assignments, confidentiality agreements, material transfer agreements, research collaborations and licenses to protect
our product candidates. For a more comprehensive discussion of the risks related to our intellectual property, please see Item 3. D. “ Risk
Factors - Risks Related to Our Intellectual Property.”

Competition

The biotechnology and pharmaceutical
industries are characterized by rapidly advancing technologies and intense competition. While we believe that our knowledge, experience
and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including
major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public
and private research institutions, which may in the future develop products to treat those diseases that we currently or, in the future,
seek to treat. Any product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies
that may become available in the